Mori Shinichiro, Shinoto Makoto, Yamada Shigeru
Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Radiother Oncol. 2014 May;111(2):258-63. doi: 10.1016/j.radonc.2014.02.014. Epub 2014 Apr 16.
We evaluated respiratory-gated carbon-ion beam dose distribution with boost irradiation in pancreatic therapy and compared results between the passive scattering and layer-stacking (a kind of semi-active scanning) irradiation techniques.
A total of 21 patients who were treated with conventional passive carbon-ion beam for pancreatic cancer underwent 4DCT imaging under free-breathing conditions. We defined two types of clinical target volume (CTV) for the initial and boost irradiations: CTV1 included the gross tumor volume (GTV) and peripheral organs, and CTV2 included the GTV only with an added uniform 2-mm margin. Planning target volumes 1 and 2 (PTV1 and PTV2) were calculated by adding the range variation considered internal margin defined by 4DCT to the respective CTVs. The initial prescribed dose (=45.6Gy (RBE); RBE-weighted absorbed dose) was given to PTV1, and the boost dose was increased up to 26.4Gy (RBE) and given to PTV2. Dose assessments were compared between irradiation techniques using the paired t-test.
D95 (GTV, CTV2) values were increased from 44.2Gy (RBE) with the prescribed dose of 45.6Gy (RBE) to 69.8Gy (RBE) with the prescribed dose of 72.0Gy (RBE) with both irradiations. Layer-stacking irradiation reduced excessive dosing to normal tissues compared with passive scattering irradiation, particularly for boost irradiation. 1st-2nd portion V20/V40, and stomach V20 values up to the prescribed dose of 48.0, 60.0, and 52.8Gy (RBE) were smaller than those in passive scattering irradiation without boost. Kidney V15/V30 (0.6% (P=0.05)/0.1% (P>0.20) for right kidney, 10.4% (P<0.01)/3.2% (P<0.01) for left kidney), pancreas V20/V40 (88.6% (P<0.01)/83.0% (P<0.03)), duodenum 3rd-4th portion V20/V40 (23.6% (P<0.01)/9.5% (P>0.06)), and stomach V20 (16.3% (P<0.01)) values in layer-stacking irradiation were smaller than those in passive scattering irradiation up to the prescribed dose of 72.0Gy (RBE) and also smaller than those with passive scattering irradiation without boost irradiation (=45.6Gy (RBE)).
In pancreatic particle beam therapy, delivery of the prescribed dose by layer-stacking boost irradiation provides a greater reduction in excessive dose to normal tissues than delivery by passive scattering irradiation.
我们评估了呼吸门控碳离子束在胰腺癌治疗中进行追加照射时的剂量分布,并比较了被动散射和层叠(一种半主动扫描)照射技术的结果。
共有21例接受常规被动碳离子束治疗胰腺癌的患者在自由呼吸条件下进行了4DCT成像。我们为初始照射和追加照射定义了两种临床靶区体积(CTV):CTV1包括大体肿瘤体积(GTV)和周围器官,CTV2仅包括GTV并增加2mm均匀边界。计划靶区体积1和2(PTV1和PTV2)通过将4DCT定义的内部边界所考虑的射程变化加到各自的CTV上来计算。初始处方剂量(=45.6Gy(RBE);RBE加权吸收剂量)给予PTV1,追加剂量增加至26.4Gy(RBE)并给予PTV2。使用配对t检验比较两种照射技术之间的剂量评估。
两种照射方式下,D95(GTV,CTV2)值从处方剂量45.6Gy(RBE)时的44.2Gy(RBE)增加到处方剂量72.0Gy(RBE)时的69.8Gy(RBE)。与被动散射照射相比,层叠照射减少了对正常组织的过量照射,特别是在追加照射时。在处方剂量分别为48.0、60.0和52.8Gy(RBE)时,第1 - 2部分的V20/V40以及胃的V20值小于无追加照射的被动散射照射。在处方剂量达72.0Gy(RBE)时,层叠照射中右肾的V15/V30(0.6%(P = 0.05)/0.1%(P > 0.20))、左肾的V15/V30(10.4%(P < 0.01)/3.2%(P < 0.01))、胰腺的V20/V40(88.6%(P < 0.01)/83.0%(P < 0.03))、十二指肠第3 - 4部分的V20/V40(23.6%(P < 0.01)/9.5%(P > 0.06))以及胃的V20(16.3%(P < 0.01))值均小于被动散射照射,且也小于无追加照射的被动散射照射(=45.6Gy(RBE))。
在胰腺癌粒子束治疗中,与被动散射照射相比,层叠追加照射在给予处方剂量时能更大程度地减少对正常组织的过量照射。